Semin Thromb Hemost 2013; 39(07): 697-701
DOI: 10.1055/s-0033-1353996
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hemophilia A and Hemophilia B: Different Types of Diseases?

Elena Santagostino
1   Hemophilia and Thrombosis Center “A. Bianchi Bonomi,” IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy
Maria Rosaria Fasulo
1   Hemophilia and Thrombosis Center “A. Bianchi Bonomi,” IRCCS Cà Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
08 September 2013 (online)


Hemophilia A and B are traditionally considered clinically indistinguishable; however, differences in bleeding frequency, clinical scores, use of prophylaxis, and need for orthopedic surgery have been reported, suggesting that the bleeding tendency associated with factor IX deficiency may be less severe with consequent better outcomes in the long term.

Hemophilia A and B show their own peculiar aspects, not only in terms of epidemiological and clinical features, including inhibitor incidence and associated symptoms, but also with respect to molecular defects. The type of factor VIII/IX mutation is a major determinant of the bleeding tendency as well as of the risk of inhibitor formation; thus, there is a biological plausibility behind the different clinical expression of these two forms of congenital hemophilia. The distinction of various bleeding phenotypes in hemophilia has considerable therapeutic implications; therefore, further research in this field is required to optimize treatment regimens.

  • References

  • 1 Mannucci PM, Tuddenham EGD. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
  • 2 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379 (9824) 1447-1456
  • 3 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16 (1) 20-32
  • 4 White II GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85 (3) 560
  • 5 Aledort LM, Haschmeyer RH, Pettersson H. The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236 (4) 391-399
  • 6 Aznar JA, Magallón M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6 (3) 170-176
  • 7 Solimeno LP, Mancuso ME, Pasta G, Santagostino E, Perfetto S, Mannucci PM. Factors influencing the long-term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution. Br J Haematol 2009; 145 (2) 227-234
  • 8 Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008; 34 (1) 128-141
  • 9 Schulman S, Eelde A, Holmström M, Ståhlberg G, Odeberg J, Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6 (7) 1113-1121
  • 10 Lowe GD, Ludlam CA. Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost 2008; 6 (11) 1982-1983
  • 11 Tagariello G, Iorio A, Santagostino E , et al; Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114 (4) 779-784
  • 12 Makris M. Is VIII worse than IX?. Blood 2009; 114 (4) 750-751
  • 13 Haemophilia A—Summary of Unique Mutations reported. Available at: . Accessed April 26, 2013
  • 14 Margaglione M, Castaman G, Morfini M , et al; AICE-Genetics Study Group. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008; 93 (5) 722-728
  • 15 Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361 (9371) 1801-1809
  • 16 Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. Factor IX Mutation Database. Available at: . Accessed April 26, 2013
  • 17 Ljung R, Petrini P, Tengborn L, Sjörin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113 (1) 81-86
  • 18 Santagostino E, Mancuso ME, Tripodi A , et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (4) 737-743
  • 19 van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11 (5) 438-443
  • 20 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (1) 25-32
  • 21 Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD. Association of Hemophilia Clinic Directors of Canada (AHCDC); Canadian Association of Nurses in Hemophilia Care (CANHC). The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14 (5) 923-930
  • 22 Quick AJ, Hussey CV. Hemophilia B (PTC deficiency, or Christmas disease). AMA Arch Intern Med 1959; 103 (5) 762-775
  • 23 Tagliaferri A, Di Perna C, Franchini M, Rivolta GF, Pattacini C. Hemophilia severity score system: validation from an Italian Regional Hemophilia Reference Center. J Thromb Haemost 2009; 7 (4) 720-722
  • 24 Nagel K, Walker I, Decker K, Chan AK, Pai MK. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia 2011; 17 (6) 872-874
  • 25 den Uijl IEM, Roosendaal G, Fischer K. Insufficient evidence to suggest less stringent therapy in hemophilia B?. Blood 2009; 114 (23) 4907 , author reply 4907–4908
  • 26 White II GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78 (1) 261-265
  • 27 Ewenstein BM, Joist JH, Shapiro AD , et al; Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42 (2) 190-197
  • 28 Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87 (3) 431-435
  • 29 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (1) 2-10
  • 30 National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). National Hemophilia Foundation Web site. Available at: November 4, 2007
  • 31 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
  • 32 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (3) 305-315
  • 33 Astermark J. Prevention and prediction of inhibitor risk. Haemophilia 2012; 18 (Suppl. 04) 38-42
  • 34 Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4 (4) 574-576
  • 35 Ewenstein BM, Takemoto C, Warrier I , et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89 (3) 1115-1116
  • 36 Nathwani AC, Tuddenham EG, Rangarajan S , et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365 (25) 2357-2365
  • 37 Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118 (10) 2695-2701
  • 38 Shapiro AD, Ragni MV, Valentino LA , et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119 (3) 666-672
  • 39 Santagostino E, Negrier C, Klamroth R , et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120 (12) 2405-2411